Treatment of Myopic Progression
AssigneeUniversity of Utah Research Foundation
InventorsRandon Michael Burr, Balamurali K. Ambati, Sarah A. Molokhia
Life of this patent
Estimating the term…
Abstract
An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.
Claims22
1-21. (canceled)
A method of increasing corneal biomechanical strength in a myopic eye, comprising:
- administering to the myopic eye an ophthalmic composition comprising:
- a copper-containing agent;
- and
- a pharmaceutically acceptable carrier,
- wherein administration of the ophthalmic composition reduces corneal radial strain relative to an untreated cornea.
A method of remodeling a myopic cornea, comprising:
- administering to an eye of a subject an ophthalmic composition comprising:
- a copper-containing agent;
- and
- a pharmaceutically acceptable carrier,
- wherein administration of the ophthalmic composition decreases corneal diopter relative to baseline.
A method of increasing collagen crosslink density in a cornea of a myopic eye, comprising:
- administering to the eye an ophthalmic composition comprising:
- a copper-containing agent;
- and
- a pharmaceutically acceptable carrier,
- wherein administration increases lysinonorleucine (LNL) crosslink density in the cornea relative to an untreated cornea.
Dependencies are inferred from the claim text.